Genomic Vision to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum
12 Novembre 2015 - 5:45PM
Business Wire
Genomic Vision (Paris:GV) a French molecular diagnostics company
specializing in the development of diagnostic tests for genetic
diseases and cancers based on molecular combing technology,
announces that Company management will participate at the Canaccord
Genuity 2015 Medical Technology & Diagnostics Forum taking
place on November 19th at the Westin Grand Central Hotel in New
York City. Aaron Bensimon, Ph.D., CEO & President of Genomic
Vision, will deliver the Company’s corporate presentation on
Thursday, November 19th at 11:40 a.m. Eastern Time (5:40 p.m.
CET).
The Company’s presentation will be webcast live on the internet
and can be accessed by visiting the Investor Relations section of
the Company’s website at www.genomicvision.com. A replay of the
webcast will be archived on the Genomic Vision website for 90 days
following the presentation.
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics
company specialized in the development of diagnostic tests for
genetic diseases and cancers based on molecular combing. Using this
innovative technology that allows the direct visualization of
individual DNA molecules, Genomic Vision detects quantitative and
qualitative variations in the genome that are at the origin of
numerous serious pathologies. The Company is developing a solid
portfolio of tests that notably target breast cancer and cancer of
the colon. Since 2013, the Company has marketed the CombHeliX FSHD
test for identifying a myopathy that is difficult to detect,
Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks
to a strategic alliance with Quest Diagnostics, the American leader
in diagnostic laboratory tests, and in France. Genomic Vision has
been listed on Compartment C of Euronext Paris since April
2014.
For further information, please go to www.genomicvision.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151112005338/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEO+33 1 49 08 07
50investisseurs@genomicvision.comorLHAInvestor Relations
USAnne Marie Fields,
SVP212-838-3777afields@lhai.comorNewCapInvestor Relations /
Strategic CommunicationsDušan Orešanský / Emmanuel Huynh+33 1 44 71
94 92gv@newcap.fr
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Goldfield Corp (American Stock Exchange): 0 recent articles
Plus d'articles sur Goldfield